The Role of Mitogen-Activated Protein Kinase-Activated Protein Kinases (MAPKAPKs) in Inflammation

Serhan, C.N., and Ward, P.A. (2010). Fundamentals of Inflammation, Cambridge University Press. [1st].

DiDonato, 2012, NF-kB and the link between inflammation and cancer, Immunol. Rev., 246, 379, 10.1111/j.1600-065X.2012.01099.x

Kyriakis, 2012, Mammalian MAPK signal transduction pathways activated by stress and inflammation: A 10-year update, Physiol. Rev., 92, 689, 10.1152/physrev.00028.2011

Newton, 2012, Signaling in innate immunity and inflammation, Cold Spring Harb. Perspect. Biol., 4, a006049, 10.1101/cshperspect.a006049

Plenge, 2012, JAK and STAT signaling molecules in immunoregulation and immune-mediated disease, Immunity, 36, 542, 10.1016/j.immuni.2012.03.014

Cargnello, 2011, Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases, Microbiol. Mol. Biol. Rev., 75, 50, 10.1128/MMBR.00031-10

Anjum, 2008, The RSK family of kinases: Emerging roles in cellular signaling, Nat. Rev. Mol. Cell. Biol., 9, 747, 10.1038/nrm2509

Arthur, 2008, MSK activation and physiological roles, Front. Biosci., 13, 5866, 10.2741/3122

Buxade, 2008, The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases), Front. Biosci., 13, 5359, 10.2741/3086

Carriere, 2008, The RSK factors of activating the Ras/MAPK signaling cascade, Front. Biosci., 13, 4258, 10.2741/3003

Ronkina, 2008, MK2 and MK3—A pair of isoenzymes, Front Biosci., 13, 5511, 10.2741/3095

Kostenko, 2011, Physiological roles of mitogen-activated-protein-kinase-activated p38-regulated/activated protein kinase, World J. Biol. Chem., 2, 73, 10.4331/wjbc.v2.i5.73

Gaestel, 2006, MAPKAP kinases- MKs- two’s company, three’s a crowd, Nat. Rev. Mol. Cell. Biol., 7, 120, 10.1038/nrm1834

Kotlyarov, 1999, MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis, Nat. Cell. Biol., 1, 94, 10.1038/10061

Ronkina, 2007, The mitogen-activated protein kinase (MAPK)-activated protein kinases MK2 and MK3 cooperate in stimulation of tumor necrosis factor biosynthesis and stabilization of p38 MAPK, Mol. Cell. Biol., 27, 170, 10.1128/MCB.01456-06

Shiryaev, 2010, Mitogen-activated protein kinase p38 and MK2, MK3 and MK5: ménage à trois or ménage à quatre?, Cell. Signal., 22, 1185, 10.1016/j.cellsig.2010.03.002

Kostenko, 2012, Tumor promoting and suppressing roles of the atypical signalling pathway ERK3/4-MK5, J. Mol. Signal., 7, 9, 10.1186/1750-2187-7-9

Shiryaev, 2012, Septin 8 is an interaction partner and in vitro substrate of MK5, World J. Biol. Chem., 3, 98, 10.4331/wjbc.v3.i5.98

Baeuerle, 1997, NF-kB as a frequent target for immunosuppressive and anti-inflammatory molecules, Adv. Immunol., 65, 111

Barnes, 1997, Nuclear factor-kappab: A pivotal transcription factor in chronic inflammatory diseases, N. Engl. J. Med., 336, 1066, 10.1056/NEJM199704103361506

Baeuerle, 1996, NF-kB: Ten years after, Cell, 87, 13, 10.1016/S0092-8674(00)81318-5

Ghoda, 1997, The 90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal regulatory domain of the IkappaBalpha and stimulates its degradation in vitro, J. Biol. Chem., 272, 21281, 10.1074/jbc.272.34.21281

Schouten, 1997, IkappaB alpha is a target for the mitogen-activated 90 kDa ribosomal S6 kinase, EMBO J., 16, 3133, 10.1093/emboj/16.11.3133

Han, 1999, Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factor, Circ. Res., 84, 695, 10.1161/01.RES.84.6.695

Suzuki, 2003, Inflammation and angiotensin II, Int. J. Biochem. Cell Biol., 35, 881, 10.1016/S1357-2725(02)00271-6

Xu, 2011, Angiotensin II modulates interleukin-1b-induced inflammatory gene expression in vascular smooth muscle cells via interfering with ERK-NF-kB crosstalk, Biochem. Biophys. Res. Commun., 410, 543, 10.1016/j.bbrc.2011.06.021

Doyen, 2010, Tumor necrosis factor receptor-associated factor-6 and ribosomal S6 kinase intracellular pathways link the angiotensin II AT1 receptor to the phosphorylation and activation of the IkB kinase complex in vascular smooth muscle cells, J. Biol. Chem., 285, 30708, 10.1074/jbc.M110.126433

Panta, 2004, ATM and the catalytic subunit of DNA-dependent protein kinase activate NF-kappaB through a common MEK/extracellular signal-regulated kinase/pp90(rsk) signaling pathway in response to distinct forms of DNA damage, Mol. Cell. Biol., 24, 1823, 10.1128/MCB.24.5.1823-1835.2004

Zhang, 2005, A new cellular signaling mechanism for angiotensin II activation of NF-kB: An IkB-independent, RSK-mediated phosphorylation of p65, Arterioscler. Thromb. Vasc. Biol., 25, 1148, 10.1161/01.ATV.0000164624.00099.e7

Zhang, 2005, Dual pathways for nuclear factor kappaB activation by angiotensin II in vascular smooth muscle: Phosphorylation of p65 by IkappaB kinase and ribosomal kinase, Circ. Res., 97, 975, 10.1161/01.RES.0000190589.52286.41

Bohuslav, 2004, p53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1, J. Biol. Chem., 279, 26115, 10.1074/jbc.M313509200

Vergnolle, 2004, A role for proteinase-activated receptor-1 in inflammatory bowel disease, J. Clin. Invest., 114, 1444, 10.1172/JCI21689

Hou, 1998, Immunolocalization of protease-activated receptor-2 in skin: Receptor activation stimulates interleukin-8 secretion by keratinocytes in vitro, Immunology, 94, 356, 10.1046/j.1365-2567.1998.00528.x

Asokananthan, 2002, Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells, J. Immunol., 168, 3577, 10.4049/jimmunol.168.7.3577

Wang, 2010, Proteinase-activated receptors induce interleukin-8 expression by intestinal epithelial cells through ERK/RSK90 activation and histone acetylation, FASEB J., 24, 1971, 10.1096/fj.09-137646

Eliopoulos, 2002, Induction of COX-2 by LPS in macrophages is regulated by Tpl2-dependent CREB activation signals, EMBO J., 21, 4831, 10.1093/emboj/cdf478

Tiraloche, 1999, Lipopolysaccharide modulates cyclooxygenase-2 transcriptionally and posttranscriptionally in human macrophages independently from endogenous IL-1b and TNF-a, J. Immunol., 163, 963, 10.4049/jimmunol.163.2.963

Gilroy, 2000, New insights into the role of COX2 in inflammation, J. Mol. Med., 78, 121, 10.1007/s001090000094

Agarwal, 2009, Eicosanoids in inflammation and cancer: the role of COX-2, Expert Rev. Clin. Immunol., 5, 145, 10.1586/1744666X.5.2.145

Zaru, 2007, The MAPK-activated kinase Rsk controls an acute Toll-like receptor signaling response in dendritic cells and is activated through two distinct pathways, Nat. Immunol., 8, 1227, 10.1038/ni1517

Wang, 2010, Mapping of phosphorylation sites in human MSK1 activated by a novel interaction with MRK-beta, Electrophoresis, 31, 1283, 10.1002/elps.200900637

Vermeulen, 2003, Transcriptional activation of NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1), EMBO J., 22, 1313, 10.1093/emboj/cdg139

Chen, 2005, NF-kappaB RelA phosphorylation regulates RelA acetylation, Mol. Cell. Biol., 25, 7966, 10.1128/MCB.25.18.7966-7975.2005

Gorska, 2007, MK2 controls the level of negative feedback in the NF-kB pathway and is essential for vascular permeability and airway inflammation, J. Exp. Med., 204, 1637, 10.1084/jem.20062621

Reber, 2009, Ser276 phosphorylation of NF-kB p65 by MSK1 controls SCF expression in inflammation, PLoS One, 4, e4393, 10.1371/journal.pone.0004393

Quivy, 2004, Regulation at multiple levels of NF-kB-mediated transactivation by protein acetylation, Biochem. Pharmacol., 68, 1221, 10.1016/j.bcp.2004.05.039

Spooren, 2010, Hunting for serine 276-phosphorylated p65, J. Biomed. Biotechnol., 2010, 275892, 10.1155/2010/275892

Gesser, 2007, Dimethylfumarate specifically inhibits the mitogen and stress activated kinases 1 and 2 (MSK1/2). Possible role for its anti-psoriatic effect, J. Invest. Dermatol., 127, 2129, 10.1038/sj.jid.5700859

Seidel, 2011, IkBa glutathionylation and reduced histone H3 phosphorylation inhibit eotaxin and RANTES, Eur. Respir. J., 38, 1444, 10.1183/09031936.00129610

Terazawa, 2012, Astaxanthin attenuates the UVB-induced secretion of prostaglandin E2 and interleukin-8 in human keratinocytes by interrupting MSK1 phosphorylation in a ROS depletion-independent manner, Exp. Dermatol., 21, 11, 10.1111/j.1600-0625.2012.01496.x

Ospelt, 2010, TLRs and chronic inflammation, Int. J. Biochem. Cell. Biol., 42, 495, 10.1016/j.biocel.2009.10.010

Drexler, 2010, The role of Toll-like receptors in chronic inflammation, Int. J. Biochem. Cell. Biol., 42, 506, 10.1016/j.biocel.2009.10.009

Ananieva, 2008, The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signalling, Nat. Immunol., 9, 1028, 10.1038/ni.1644

Edwards, 2010, The multikinase inhibitor Sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE2 in murine macrophages, Int. Immunopharmacol., 10, 1220, 10.1016/j.intimp.2010.07.002

Kim, 2008, The kinase p38alpha serves cell type-specific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression, Nat. Immunol., 9, 1019, 10.1038/ni.1640

Darragh, 2010, MSK1 regulates the transcription of IL-1ra in response to TLR activation in macrophages, Biochem. J., 425, 595, 10.1042/BJ20091062

Carl, 2004, Role of endogenous IL-10 in LPS-induced STAT3 activation and IL-1 receptor antagonist gene expression, J. Leukoc. Biol., 76, 735, 10.1189/jlb.1003526

Zheng, 2001, IL-11: Insights in asthma from overexpression transgenic modelling, J. Allergy Clin. Immunol., 108, 489, 10.1067/mai.2001.118510

Suzuki, 2007, Expression of interleukin-17F in a mouse model of allergic asthma, Int. Arch. Allergy Immunol., 143, 89, 10.1159/000101413

Barnes, 2008, Immunology of asthma and chronic obstructive pulmonary disease, Nat. Rev. Immunol., 8, 183, 10.1038/nri2254

Kawaguchi, 2009, Role of interleukin-17F in asthma, Inflamm. Allergy Drug Targets, 8, 383, 10.2174/1871528110908050383

Kawaguchi, 2009, IL-17F-induced IL-11 release in bronchial epithelial cells via MSK1-CREB pathway, Am. J. Physiol. Lung Cell. Mol. Physiol., 296, L804, 10.1152/ajplung.90607.2008

Hoshino, 1998, Inhaled corticosteroid reduced lamina reticularis of the basement membrane by modulation of insulin-like growth factor (IGF)-I expression in bronchial asthma, Clin. Exp. Allergy, 28, 568, 10.1046/j.1365-2222.1998.00277.x

Kawaguchi, 2010, Induction of insulin-like growth factor-I by interleukin-17F in bronchial epithelial cells, Clin. Exp. Allergy, 40, 1036, 10.1111/j.1365-2222.2010.03527.x

Zhang, 2001, MSK1 and JNKs mediate phosphorylation of STAT3 in UVA-irradiated mouse epidermal JB6 cells, J. Biol. Chem., 276, 42534, 10.1074/jbc.M106044200

Wierenga, 2003, Erythropoietin-induced serine 727 phosphorylation of STAT3 in erythroid cells is mediated by a MEK-, ERK-, and MSK1-dependent pathway, Exp. Hematol., 31, 398, 10.1016/S0301-472X(03)00045-6

Hefner, 2000, Serine 727 phosphorylation and activation of cytosolic phospholipase A2 by MNK1-related protein kinase, J. Biol. Chem., 275, 37542, 10.1074/jbc.M003395200

Bertelsen, 2011, The role of mitogen- and stress-activated protein kinase 1 and 2 in chronic skin inflammation in mice, Exp. Dermatol., 20, 140, 10.1111/j.1600-0625.2010.01153.x

Chang, 2011, Mice lacking MSK1 and MSK2 show reduced skin tumor development in a two-stage chemical carcinogenesis model, Cancer Invest., 29, 240, 10.3109/07357907.2010.550594

Vermeulen, 2009, The versatile role of MSKs in transcriptional regulation, Trends Biochem. Sci., 34, 311, 10.1016/j.tibs.2009.02.007

Syrbu, 1999, Phosphorylation of cytosolic phospholipase A2 and the release of arachidonic acid in human neutrophils, J. Immunol., 162, 2334, 10.4049/jimmunol.162.4.2334

Niknami, 2009, Molecules in focus: Cytosolic phospholipase A2-alpha, Int. J. Biochem. Cell Biol., 41, 994, 10.1016/j.biocel.2008.07.017

Parra, 2005, The Mnks are novel components in the control of TNF alpha biosynthesis and phosphorylate and regulate hnRNP A1, Immunity, 23, 177, 10.1016/j.immuni.2005.06.009

Andersson, 2006, Posttranscriptional regulation of TNFalpha expression via eukaryotic initiation factor 4E (eIF4E) phosphorylation in mouse macrophages, Cytokine, 33, 52, 10.1016/j.cyto.2005.11.017

Rowlett, 2008, MNK kinases regulate multiple TLR pathways and innate proinflammatory cytokines in macrophages, Am. J. Physiol. Gastrointest. Liver Physiol., 294, G452, 10.1152/ajpgi.00077.2007

Ziaei, 2012, MNK1 expression increases during cellular senescence and modulates the subcellular localization of hnRNP A1, Exp. Cell Res., 318, 500, 10.1016/j.yexcr.2011.12.015

Lee, 1994, A protein kinase involved in the regulation of inflammatory cytokine biosynthesis, Nature, 372, 739, 10.1038/372739a0

Neininger, 2002, MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels, J. Biol. Chem., 277, 3065, 10.1074/jbc.C100685200

Culbert, 2006, MAPK-activated protein kinase 2 deficiency in microglia inhibits pro-inflammatory mediator release and resultant neurotoxicity, J. Biol. Chem., 281, 23658, 10.1074/jbc.M513646200

Thomas, 2008, MAPKAP kinase 2-deficiency prevents neurons from cell death by reducing neuroinflammation—relevance in a mouse model of Parkinson’s disease, J. Neurochem., 105, 2039, 10.1111/j.1471-4159.2008.05310.x

Tudor, 2009, The p38 MAPK pathway inhibits tristetraprolin-directed decay of interleukin-10 and pro-inflammatory mediator mRNAs in murine macrophages, FEBS Lett., 583, 1933, 10.1016/j.febslet.2009.04.039

Schottelius, 2010, The role of mitogen-activated protein kinase-activated protein kinase 2 in the p38/TNF-a pathway of systemic and cutaneous inflammation, J. Invest. Dermatol., 130, 481, 10.1038/jid.2009.218

Bode, 2012, The macrophage response towards LPS and its control through the p38MAPK-STAT3 axis, Cell. Signal., 24, 1185, 10.1016/j.cellsig.2012.01.018

Johansen, 2006, Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2, J. Immunol., 176, 1431, 10.4049/jimmunol.176.3.1431

Jagielska, 2012, Interleukin-1b assembles a proangiogenic signal module consisting of caveolin-1, tumor necrosis factor receptor-associated factor 6, p38-mitogen-activated protein kinase (MAPK), and MAPK-activated protein kinase 2 in endothelial cells, Arterioscler. Thromb. Vasc. Biol., 32, 1280, 10.1161/ATVBAHA.111.243477

Rousseau, 2002, Inhibition of SAPK2a/p38 prevents hnRNP A0 phosphorylation by MAPKAP-K2 and its interaction with cytokine mRNAs, EMBO J., 21, 6505, 10.1093/emboj/cdf639

Chrestensen, 2004, MAPKAP kinase 2 phosphorylates tristetraprolin on in vivo sites including Ser178, a site required for 14-3-3 binding, J. Biol. Chem., 279, 10176, 10.1074/jbc.M310486200

Clement, 2011, Phosphorylation of tristetraprolin by MK2 impairs AU-rich element mRNA decay by preventing deadenylase recruitment, Mol. Cell. Biol., 31, 256, 10.1128/MCB.00717-10

Tran, 2003, Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by mitogen-activated protein kinase-activated protein kinase 2, Mol. Cell. Biol., 23, 7177, 10.1128/MCB.23.20.7177-7188.2003

Stoecklin, 2004, MK2-induced tristetraprolin: 14–3-3 complexes prevent stress granule association and ARE-mRNA decay, EMBO J., 23, 1313, 10.1038/sj.emboj.7600163

Ronkina, 2010, MAPKAP kinases MK2 and MK3 in inflammation: Complex regulation of TNF biosynthesis via expression and phosphorylation of tristetraprolin, Biochem. Pharmacol., 80, 1915, 10.1016/j.bcp.2010.06.021

Tiedje, 2012, The p38/MK2-driven exchange between tristetraprolin and HuR regulates AU-rich element-dependent translation, PLoS Genet., 8, e1002977, 10.1371/journal.pgen.1002977

Marchese, 2010, MAPKAP kinase 2 blocks tristetraprolin-directed mRNA decay by inhibitingCAF1 deadenylase recruitment, J. Biol. Chem., 285, 27590, 10.1074/jbc.M110.136473

Hitti, 2006, Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element, Mol. Cell. Biol., 26, 2399, 10.1128/MCB.26.6.2399-2407.2006

Ronkina, 2011, Stress induced gene expression: A direct role for MAKAPK kinases in transcriptional activation of immediate early genes, Nucleic Acids Res., 39, 2503, 10.1093/nar/gkq1178

Winzen, 1999, The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism, EMBO J., 18, 4969, 10.1093/emboj/18.18.4969

Winzen, 2007, Functional analysis of KSRP interaction with the AU-rich element of interleukin-8 and identification of inflammatory mRNA targets, Mol. Cell. Biol., 27, 8388, 10.1128/MCB.01493-07

Stoecklin, 2008, Genome-wide analysis identifies interleukin-10 mRNA as target of tristetraprolin, J. Biol. Chem., 283, 11689, 10.1074/jbc.M709657200

Ogilvie, 2009, Tristetraprolin mediates interferon-gamma mRNA decay, J. Biol. Chem., 284, 11216, 10.1074/jbc.M901229200

Zhao, 2011, Tristetraprolin regulates interleukin-6 expression through p38 MAPK-dependent affinity changes with mRNA 3’ untranslated region, J. Interferon Cytokine Res., 31, 629, 10.1089/jir.2010.0154

Xie, 2002, Heat shock factor 1 represses transcription of the IL-1beta gene through physical interaction with the nuclear factor of interleukin 6, J. Biol. Chem., 277, 11802, 10.1074/jbc.M109296200

Wang, 2006, Phosphorylation of HSF1 by MAPK-activated protein kinase 2 on serine 121, inhibits transcriptional activity and promotes HSP90 binding, J. Biol. Chem., 281, 782, 10.1074/jbc.M505822200

Scheller, 2011, The pro- and anti-inflammatory properties of the cytokine interleukin-6, Biochim. Biophys. Acta, 1813, 878, 10.1016/j.bbamcr.2011.01.034

Radtke, 2010, Cross-regulation of cytokine signalling: Pro-inflammatory cytokines restrict IL-6 signalling through receptor internalisation and degradation, J. Cell Sci., 123, 947, 10.1242/jcs.065326

Heo, 2013, Phosphorylation of protein inhibitor of activated STAT1 (PIAS1) by MAPK-activated protein kinase-2 inhibits endothelial inflammation via increasing both PIAS1 transrepression and SUMO E3 ligase activity, Arteriodcler. Thromb. Vasc. Biol., 33, 321, 10.1161/ATVBAHA.112.300619

Liu, 2005, Negative regulation of NF-kappaB signalling by PIAS1, Mol. Cell. Biol., 25, 1113, 10.1128/MCB.25.3.1113-1123.2005

Stokoe, 1992, Identification of MAPKAP kinase 2 as a major enzyme responsible for the phosphorylation of the small mammalian heat shock proteins, FEBS Lett., 313, 307, 10.1016/0014-5793(92)81216-9

Clifton, 1996, A comparison of the substrate specificity of MAPKAP kinase-2 and MAPKAP kinase-3 and their activation by cytokines and cellular stress, FEBS Lett., 392, 209, 10.1016/0014-5793(96)00816-2

Kostenko, 2009, Heat shock protein 27 phosphorylation: Kinases, phosphatases, functions and pathology, Cell. Mol. Life Sci., 66, 3289, 10.1007/s00018-009-0086-3

Shiryaev, 2011, Distinct roles of MK2 and MK5 in cAMP/PKA- and stress/p38MAPK-induced heat shock protein 27 phosphorylation, J. Mol. Signal., 6, 4, 10.1186/1750-2187-6-4

Kato, 2011, Role of HSP27 in tumor necrosis factor-a-stimulated interleukin-6 synthesis in osteoblasts, Int. J. Mol. Med., 28, 887

Tanabe, 2010, Phosphorylation status of heat shock protein 27 regulates the interleukin-1b-induced interleukin-6 synthesis in C6 glioma cells, Neuroscience, 170, 1028, 10.1016/j.neuroscience.2010.08.014

Alford, 2007, Heat shock protein 27 functions in inflammatory gene expression and transforming growth factor-beta-activated kinase-1 (TAK-1)-mediated signaling, J. Biol. Chem., 282, 6232, 10.1074/jbc.M610987200

Lasa, 2000, Regulation of cyclooxygenase 2 mRNA stability by the mitogen-activated protein kinase p38 signaling cascade, Mol. Cell. Biol., 20, 4265, 10.1128/MCB.20.12.4265-4274.2000

De, 2000, Exaggerated human monocyte IL-10 concomitant to minimal TNF-alpha induction by heat-shock protein (Hsp27) suggests Hsp27 is primarily an antiinflammatory stimulus, J. Immunol., 165, 3951, 10.4049/jimmunol.165.7.3951

Park, 2003, Heat shock protein 27 association with the I kappa B kinase complex regulates tumor necrosis factor alpha-induced NF-kappa B activation, J. Biol. Chem., 278, 35272, 10.1074/jbc.M305095200

Sinsimer, 2008, Chaperone Hsp27, a novel subunit of AUF1 protein complexes, functions in AU-rich element-mediated mRNA decay, Mol. Cell. Biol., 28, 5223, 10.1128/MCB.00431-08

Kubisch, 2004, Overexpression of heat shock protein Hsp27 protects against cerulean-induced pancreatitis, Gastroenterology, 127, 275, 10.1053/j.gastro.2004.04.005

Funding, 2009, Reduced oxazolone-induced skin inflammation in MAPKAP kinase 2 knockout mice, J. Invest. Dermatol., 129, 891, 10.1038/jid.2008.322

Johansen, 2009, MK2 regulates the early stages of skin tumor promotion, Carcinogenesis, 30, 2100, 10.1093/carcin/bgp238

Fyhrquist, 2010, MK2 signaling: lessons on tissue specificity in modulation of inflammation, J. Invest. Dermatol., 130, 342, 10.1038/jid.2009.372

Li, 2011, Unfolded protein response signaling and MAP kinase pathways underlie pathogenesis of arsenic-induced cutaneous inflammation, Cancer Prev. Res., 4, 2101, 10.1158/1940-6207.CAPR-11-0343

Pierce, 2011, Arsenic exposure, dietary patterns, and skin lesion risk in Bangladesh: A prospective study, Am. J. Epidemiol., 173, 345, 10.1093/aje/kwq366

Tietz, 2006, Gene deletion of MK2 inhibits TNF-a and IL-6 and protects against cerulein-induced pancreatitis, Am. J. Physiol. Gastrointest. Liver Physiol., 290, G1298, 10.1152/ajpgi.00530.2005

Li, 2009, Regulation of HSP60 and the role of MK2 in a new model of severe experimental pancreatitis, Am. J. Physiol. Gastrointest. Liver Physiol., 297, G981, 10.1152/ajpgi.00225.2009

Michler, 2012, Activation of cannabinoid receptor 2 reduces inflammation in acute experimental pancreatitis via intra-acinar activation of p38 and MK2-dependent mechanisms, Am. J. Physiol. Gastrointest. Liver Physiol., 304, G181, 10.1152/ajpgi.00133.2012

Wagner, 2000, CEP-1347 inhibits caerulein-induced rat pancreatic JNK activation and ameliorates caerulein pancreatitis, Am. J. Physiol. Gastrointest. Liver Physiol., 278, G165, 10.1152/ajpgi.2000.278.1.G165

Yoshizuka, 2012, PRAK suppresses oncogenic ras-induced hematopoietic cancer development by antagonizing the JNK pathway, Mol. Cancer Res., 10, 810, 10.1158/1541-7786.MCR-11-0576

Lin, 2001, IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of anti-apoptotic gene mcl-1, Carcinogenesis, 22, 1947, 10.1093/carcin/22.12.1947

Poornima, 2006, Diabetic cardiomyopathy: The search for a unifying hypothesis, Circ. Res., 98, 596, 10.1161/01.RES.0000207406.94146.c2

Thandavarayan, 2011, Depletion of 14–3-3 protein exacerbates cardiac oxidative stress, inflammation and remodelling process via modulation of MAPK/NF-kB signalling pathways after streptozotocin-induced diabetes mellitus, Cell. Physiol. Biochem., 28, 911, 10.1159/000335805

Wang, 2002, Mitogen-activated protein kinase-activated protein (MAPKAP) kinase 2 deficiency protects brain from ischemic injury in mice, J. Biol. Chem., 277, 43969, 10.1074/jbc.M206837200

Trentham, 1977, Autoimmunity type II collagen and experimental model of arthritis, J. Exp. Med., 146, 857, 10.1084/jem.146.3.857

Hegen, 2006, MAPKAP kinase 2-deficient mice are resistant to collagen-induced arthritis, J. Immunol., 177, 1913, 10.4049/jimmunol.177.3.1913

Jagavelu, 2007, Systemic deficiency of the MAP kinase-activated protein kinase 2 reduces atherosclerosis in hypercholesterolemic mice, Circ. Res., 101, 1104, 10.1161/CIRCRESAHA.107.156075

Ebrahimian, 2011, Mitogen-activated protein kinase-activated protein kinase 2 in angiotensin II-induced inflammation and hypertension: Regulation of oxidative stress, Hypertension, 57, 245, 10.1161/HYPERTENSIONAHA.110.159889

Li, 2011, Silencing mitogen-activated protein kinase-activated protein kinase-2 arrests inflammatory bone loss, J. Pharmacol. Exp. Ther., 336, 633, 10.1124/jpet.110.172395

Jones, 2009, Mitogen-activated kinase-activated protein kinase 2 (MK2) modulates key biological pathways associated with OA disease pathology, Ostearthritis Cartilage, 17, 124, 10.1016/j.joca.2008.05.001

Braun, 2012, Mitogen-activated protein kinase 2 (MK2) regulates physiological and pathological bone turnover, J. Bone Miner. Res., 28, 936, 10.1002/jbmr.1816

Feng, 2011, The role of p38 mitogen-activated protein kinase in the pathogenesis of inflammatory bowel disease, J. Dig. Dis., 12, 327, 10.1111/j.1751-2980.2011.00525.x

Ghasemlou, 2010, Mitogen-activated protein kinase-activated protein kinase 2 (MK2) contributes to secondary damage after spinal cord injury, J. Neurosci., 30, 13750, 10.1523/JNEUROSCI.2998-10.2010

Ehlting, 2011, Distinct functions of the mitogen-activated protein (MAPKAP) kinases MK2 and MK3: MK2 mediates lipopolysaccharide-induced signal transducers and activators of transcription 3 (STAT3) by preventing negative regulatory effects of MK3, J. Biol. Chem., 286, 24113, 10.1074/jbc.M111.235275

Lang, 2005, Tuning of macrophage responses by Stat3-inducing cytokines: molecular mechanisms and consequences in infection, Immunobiology, 210, 63, 10.1016/j.imbio.2005.05.001

Shi, 2003, Elimination of protein kinase MK5/PRAK activity by targeted homologous recombination, Mol. Cell. Biol., 23, 7732, 10.1128/MCB.23.21.7732-7741.2003

Cohen, 2009, Targeting protein kinases for the development of anti-inflammatory drugs, Curr. Opin. Vell Biol., 21, 317, 10.1016/j.ceb.2009.01.015

Gaestel, 2009, Targeting innate immunity protein kinase signaling in inflammation, Nat. Rev. Drug Discov., 8, 480, 10.1038/nrd2829

Cohen, 2005, Structural bioinformatics-based design of selective, irreversible kinase inhibitors, Science, 308, 1318, 10.1126/science1108367

Maloney, 2005, Synthesis of a potent and selective inhibitor of p90 Rsk, Org. Lett., 7, 1097, 10.1021/ol0500463

Nguyen, 2006, Homology model of RSK2 N-terminal kinase domain, structure-based identification of novel RSK2 inhibitors, and preliminary common pharmacophore, Bioorg. Med. Chem., 14, 6097, 10.1016/j.bmc.2006.05.001

Smith, 2006, Influence of rhamnose substituents on the potency of SL0101, an inhibitor of the Ser/thr kinase, RSK, Bioorg. Med. Chem., 14, 6034, 10.1016/j.bmc.2006.05.009

Sapkota, 2007, BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo, Biochem. J., 401, 29, 10.1042/BJ20061088

Shan, 2010, Synthesis of SL0101 carbasugar analogues: carbasugars via Pd-catalyzed cyclitolization and post-cyclitolization transformations, Org. Lett., 12, 2986, 10.1021/ol101009q

Hilinski, 2012, Analogs of the RSK inhibitor SL0101: Optimization of in vitro biological stability, Bioorg. Med. Chem. Lett., 22, 3244, 10.1016/j.bmcl.2012.03.033

Bain, 2007, The selectivity of protein kinase inhibitors: A further update, Biochem. J., 408, 297, 10.1042/BJ20070797

Bamford, M.J., Alberti, M.J., Bailey, N., Davies, S., Dean, D.K., Gaiba, A., Garland, S., Harling, J.D., Jung, D.K., Panchal, T.A., Parr, C.A., Steadman, J.G., Takle, A.K., Townsend, J.T., Wilson, D.M., and Witherington, J. (1H-imidazo[4,5-c]pyridine-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: A novel class of potent MSK-1-inhibitors. Bioorg. Med. Chem. Lett., 15, 3402–3406.

Bamford, M.J., Bailey, N., Davies, S., Dean, D.K., Francis, L., Panchal, T.A., Parr, C.A., Sehmi, S., Steadman, J.G., Takle, A.K., and Townsend, J.T. (1H-imidazo[4,5-c]pyridine-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Further optimisation as highly potent and selective MSK-1-inhibitors. Bioorg. Med. Chem. Lett., 15, 3407–3411.

Naqvi, 2012, Characterization of the cellular action of the MSK inhibitor SB-747651A, Biochem. J., 441, 347, 10.1042/BJ20110970

Beck, 2008, Altered subcellular distribution induced by glucocorticoids contributes to NF-kappaB inhibition, EMBO J., 27, 1682, 10.1038/emboj.2008.95

Barnes, 2009, Glucocorticoid resistance in inflammatory diseases, Lancet, 373, 1905, 10.1016/S0140-6736(09)60326-3

Knauf, 2001, Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2, Mol. Cell. Biol., 21, 5500, 10.1128/MCB.21.16.5500-5511.2001

Cherla, 2006, Shiga toxin 1-induced cytokine production is mediated by MAP kinase pathways and translation initiation factor eIF4E in the macrophage-like THP-1 cells line, J. Leukoc. Biol., 79, 397, 10.1189/jlb.0605313

Kjellerup, 2008, Pro-inflammatory cytokines release in keratinocytes is mediated through the MAPK signal-integrating kinases, Exp. Dermatol., 17, 498, 10.1111/j.1600-0625.2007.00672.x

Mourey, 2010, A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha and has oral anti-inflammatory efficacy in acute and chronic models of inflammation, J. Pharmacol. Exp. Ther., 333, 797, 10.1124/jpet.110.166173

Kosugi, 2012, Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2) as an anti-inflammatory target: discovery and in vivo activity of selective pyrazolo[1,5-a]pyrimidine inhibitors using a focused library and structure-based optimization approach, J. Med. Chem., 55, 6700, 10.1021/jm300411k

Wu, 2007, The discovery of carboline analogs as potent MAPKAP-K2 inhibitors, Bioorg. Med. Chem. Lett., 17, 4664, 10.1016/j.bmcl.2007.05.101

Schlapbach, 2008, Pyrrolo-pyrimidones: a novel class of MK2 inhibitors with potent cellular activity, Bioorg. Med. Chem. Lett., 18, 6142, 10.1016/j.bmcl.2008.10.039

Revesz, 2010, In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors, Part I, Bioorg. Med. Chem. Lett., 20, 4715, 10.1016/j.bmcl.2010.04.024

Velcicky, 2010, Novel 3-aminopyrazole inhibitors of MK-2 discovered by scaffold hopping strategy, Bioorg. Med. Chem. Lett., 20, 1293, 10.1016/j.bmcl.2009.10.138

Kaptein, 2011, Discovery of selective and orally available spiro-3-piperidyl ATP-competitive MK2 inhibitors, Bioorg. Med. Chem. Lett., 21, 3823, 10.1016/j.bmcl.2011.04.016

Huang, 2012, A three-step protocol for lead optimization: quick identification of key conformational features and functional groups in the SAR studies of non-ATP competitive MK2 (MAPKAPK2) inhibitors, Bioorg. Med. Chem. Lett., 22, 65, 10.1016/j.bmcl.2011.11.074

Coxon, 2003, MAPK-activated protein kinase-2 participates in p38 MAPK-dependent and ERK-dependent functions in human neutrophils, Cell. Signal., 15, 993, 10.1016/S0898-6568(03)00074-3

Lopes, 2009, Inhibition of HSP27 phosphorylation by a cell-permeant MAPKAP kinase 2 inhibitor, Biochem. Biophys. Res. Commun., 382, 539, 10.1016/j.bbrc.2009.03.056

Brugnano, 2011, Cell-penetrating peptides can confer biological function: regulation of inflammatory cytokines in human monocytes by MK2 inhibitor peptides, J. Control Release, 155, 128, 10.1016/j.jconrel.2011.05.007

Muto, 2012, Inhibition of mitogen activated protein kinase activated protein kinase II with MMI-0100 reduces intimal hyperplasia ex vivo and in vivo, Vascul. Pharmacol., 56, 47, 10.1016/j.vph.2011.07.008

Kostenko, 2011, The diterpenoid alkaloid noroxoaconitine is a Mapkap kinase 5 (MK5/PRAK) inhibitor, Cell. Mol. Life Sci., 68, 289, 10.1007/s00018-010-0452-1

Andrews, 2009, Small molecules against the novel target MAPKAPK5 show bone protection and anti-inflammatory activity in in vivo models of rheumatoid arthritis, Ann. Rheum. Dis., 68, 590

Anwar, 2011, The kinase inhibitor SFV785 dislocates dengue virus envelope protein from the replication complex and blocks virus assembly, PLoS One, 6, e23246, 10.1371/journal.pone.0023246

Andrews, 2012, Discovery of a series of imidazopyrazine small molecule inhibitors of the kinase MAPKAPK5, that show activity using in vitro and in vivo models of rheumatoid arthritis, Bioorg. Med. Chem. Lett., 22, 2266, 10.1016/j.bmcl.2012.01.077

Namour, 2012, Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subject, Drugs R D, 12, 141, 10.2165/11633120-000000000-00000

Westhovens, R., De Keyser, F., Rekalov, D., Nasonov, E.L., Beetens, J., Van der Aa, A., Wigerinck, P., Namour, F., Vanhoutte, F., and Durez, P. (2012). Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: A phase II, randomised double-blind, placebo-controlled, multicentre trial. Ann. Rheum. Dis.

Dong, 2008, Repression of gene expression by unphosphorylated NF-kappaB p65 through epigenetic mechanisms, Genes Dev., 22, 1159, 10.1101/gad.1657408